Skip to main navigation

About Us
Our Products
Investor Relations
News
Cumberland Emerging Technologies
Blog

About Us
Our Products
Investor Relations
News
Cumberland Emerging Technologies
Blog

Press Releases

Year

Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting

Mar 17, 2026

PDF Version

Cumberland Pharmaceuticals Reports 31% Fourth Quarter 2025 Revenue Growth

Mar 03, 2026

PDF Version

CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®

Feb 25, 2026

PDF Version

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE

Feb 24, 2026

PDF Version

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program

Feb 04, 2026

PDF Version

CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT

Dec 08, 2025

PDF Version

Cumberland Pharmaceuticals Reports 12% Year-to-Date Revenue Growth

Nov 04, 2025

PDF Version

Cumberland Pharmaceuticals to Announce Q3 2025 Financial Results & Company Update

Oct 28, 2025

PDF Version

Cumberland Pharmaceuticals Announces the Addition of an Established FDA-Approved Product to Its Commercial Portfolio

Oct 20, 2025

PDF Version

Cumberland Pharmaceuticals' Vibativ® Added to National Group Purchasing Agreement with Premier, Inc.

Oct 13, 2025

PDF Version

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 20

© 2026 Cumberland Pharmaceuticals, Inc. All Rights Reserved.

Privacy Policy

Accessibility Statement

Terms of Use